2291360-73-9
Chemical Structure
NVP-DKY709
- CAS No.: 2291360-73-9
- Formula:C25H27N3O3
- Molecular Weight:417.50
IUPAC Name: 3-(5-(1-benzylpiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
InChIKey: OMISHRJQMYQPMG-UHFFFAOYSA-N
SMILES: O=C1CCC(C(N1)=O)N2CC3=CC(C4CCN(CC4)CC5=CC=CC=C5)=CC=C3C2=O
Biological Activity: NVP-DKY709 is an orally active and selective IKZF2 molecular glue degrader with the Dmax and DC50 of 53% and 4 nM, respectively. In addition, NVP-DKY709 can degrade IKZF4 (DC50: 13 nM) and SALL4 (DC50: 2 nM). NVP-DKY709 exerts anti-tumor activity by binding with CRBN to change conformation and recruit and degrade IKZF2[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NVP-DKY709 | 99.66% | NVP-DKY709 is an orally active and selective IKZF2 molecular glue degrader with the Dmax and DC50 of 53% and 4 nM, respectively. In addition, NVP-DKY709 can degrade IKZF4 (DC50: 13 nM) and SALL4 (DC50: 2 nM). NVP-DKY709 exerts anti-tumor activity by binding with CRBN to change conformation and recruit and degrade IKZF2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.77
HY-W11155422-(2,6-Dioxopiperidin-3-yl)phthalimidine-1-(piperidin-4-ylmethyl)piperidine -
Similarity Score 0.74
HY-W8745852-(2,6-Dioxopiperidin-3-yl)phthalimidine-piperidine -
Similarity Score 0.74
HY-W594189Desamino lenalidomide-Pip hydrochloride -
Similarity Score 0.69
HY-W11152202-(2,6-Dioxopiperidin-3-yl)phthalimidine-azetidine -
Similarity Score 0.69
HY-W1115223Desamino lenalidomide-C-piperazine -
Similarity Score 0.68
HY-185300IKZF2-degrader 4 -
Similarity Score 0.65
HY-173525E3 Ligase Ligand-linker Conjugate 180 -
Similarity Score 0.65
HY-168684E3 Ligase Ligand-linker Conjugate 136 -
Similarity Score 0.64
HY-W957152Deoxy-thalidomide-C4-NH2 -
Explore the MedChemAI to find more analogs
References
- [1]. Bonazzi S, et al. Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. Cell Chem Biol. 2023 Mar 16;30(3):235-247.e12. [Content Brief]
- [2]. Simone BONAZZI, et al. Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives. WO2020128972 A1.
